Collaborating Leaders in AI-Driven Clinical Data and Oncology Testing
Integrating ConcertAI’s Advanced Analytics with NeoGenomics’ Precision Diagnostics
Hematological malignancies impact millions of patients worldwide and hundreds of thousands in the United States. The long term and highly heterogenous nature of the disease has made classical approaches to RWD analysis challenging.
The Leader in RWD together with the leader in hematological testing and interpretation to create the reference data sets for hematological research and a new system of solutions for hematological clinical trials.
NeoGenomics has a multi-decade history in hematological testing, providing this for almost 40% of patients in certain hematological diseases; ConcertAI has the broadest EMR-derived clinical data – together they have assessed the ability provide the longitudinality, clinical depth, and biomarker coverage to create the definitive RWD for hematological research.
CLICK HERE to set up a meeting.
Read more about the collaboration – request your joint factsheet today!
Research Studies
Click on any of the images below to learn more about how ConcertAI data is being used in hematological research studies.
%20Patients%20Exposed%20to%20Specific%20Therapies.svg)
Research Progostic Value of Cytogenetics in Relapsed (Refractory) Patients Exposed to Specific Therapies
Explore Real-World Patient and Testing Journeys and Heme Healthcare Utilization
Predict Risk Scores and Survival Using Comprehensive Testing Combined with Clinical Results
Assess Racial Disparities in Treatment Patterns and Outcomes at the Molecular Level
